Selegiline Transdermal System
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Objective: To assess the effectiveness of the selegiline transdermal system (STS) in reversing HIV-induced metabolic brain injury…
Background: Cognitive impairment continues to be a significant neurologic complication of HIV infection and has been associated…
Abstract Objective: To assess the long-term safety (primary aim) and efficacy (secondary aim) of the MAO-B inhibitor Selegiline…
ABSTRACT Background: Monoamine oxidase inhibitors are well recognized as effective antidepressant agents but are rarely used due…
OBJECTIVE
Spontaneous reports of sexual side effects were infrequent during placebo-controlled clinical trials of selegiline…
The selegiline transdermal system (STS) is a monoamine oxidase inhibitor (MAOI) with unique pharmacokinetic and pharmacodynamic…
ABSTRACT The clinical use of monoamine oxidase inhibitors (MAOIs) has declined due to concerns about food and drug interactions…
Selegiline has been formulated in an acrylic polymer adhesive mixture to be employed as a constant release topical patch for…
Selegiline (SEL) is a selective, irreversible inhibitor of MAO‐B, used in the treatment of Parkinson's disease, either alone or…
This open-label, two-phase cross-over study compared the safety and pharmacokinetics of transdermally administered selegiline and…